Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

71.75 -0.25 (-0.35%)
Official Closing Price Updated: 4:15 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 692,632
Open 71.95
Bid (Size) 71.00 (5)
Ask (Size) 73.43 (1)
Prev. Close 72.00
Today's Range 70.75 - 72.36
52wk Range 33.34 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 18.7% year on year to $194.4 million. The company’s full-year revenue... 
Via StockStory
2 Growth Stocks Set to Flourishand 1 We Avoid
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory

Performance

YTD
+43.6%
+43.6%
1 Month
-1.5%
-1.5%
3 Month
-4.4%
-4.4%
6 Month
-1.3%
-1.3%
1 Year
+105.3%
+105.3%

More News

Read More
3 Low-Volatility Stocks That Fall Short
Via StockStory
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Earnings Scheduled For July 31, 2025
Via Benzinga
Corcept (NASDAQ:CORT) Misses Q2 Sales Targets
Via StockStory
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Strong Affordable Growth Pick with Solid Fundamentals
Via Chartmill
What To Expect From Corcept’s (CORT) Q2 Earnings
Via StockStory
Topics Artificial Intelligence
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years
Via Benzinga
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know
Via StockStory
Topics Lawsuit World Trade
What's Driving the Market Sentiment Around Corcept Therapeutics?
Via Benzinga
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
3 High-Flying Stocks Skating on Thin Ice
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - A Promising Affordable Growth Stock
Via Chartmill
1 Cash-Producing Stock Worth Your Attention and 2 to Ignore
Via StockStory
Here's How Much $100 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth Today
Via Benzinga
3 Russell 2000 Stocks in Hot Water
Via StockStory
CORCEPT THERAPEUTICS INC (NASDAQ:CORT) – A Strong Growth Stock with Technical Breakout Potential
Via Chartmill
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care
From Corcept Therapeutics Incorporated
Via Business Wire
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study
Via Benzinga
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
From Corcept Therapeutics Incorporated
Via Business Wire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 71.75
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 08/15/25 04:15 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 8.32B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.